Eye Test Can Identify Diabetes and Monitor Progression

Lens autofluorescence, a known marker for diabetes, can be measured by the CLEARPATH DS-120, according to a recent literature review conducted by Nilufer Koyuoglu, MD.

Dr Koyluoglu presented the findings of the review at the 15th International Congress on Vision Science and Ophthalmology on August 10, 2017, in London, England.
___________________________________________________________________________________________

RELATED CONTENT
Diabetic Retinopathy: Which anti-VEGFs Are Most Effective?
ADA Updates Treatment and Screening Guidelines for Diabetic Retinopathy
___________________________________________________________________________________________

Diabetes patients have increased lens autofluorescence, caused by the accumulation of advanced glycation end products (AGEs) in the eyes. Clinicians can measure lens autofluorescence to identify individuals with diabetes and monitor progression of the condition.

Previous research has established that the intensity of lens autofluorescence increases with age and with progression of diabetes. When exposed to light, the extent of lens autofluorescence can be detected with an optical sensor. Currently, the only technology approved to measure lens autofluorescence in the United States is the CLEARPATH DS-120.

According to Dr Koyuoglu, patients whose measurements with the CLEARPATH DS-210 exceed the 95% prediction interval should be referred to primary care for a follow-up evaluation of glycemic control. Patients between the 80% and 95% prediction intervals may benefit from an annual CLEARPATH evaluation to monitor disease progression. Patients below the 80% interval are recommended to receive another CLEARPATH evaluation in 3 years.

Additionally, according to Dr Koyuoglu, a red or orange line on the CLEARPATH evaluation indicates the patient has high lens fluorescence and high AGE accumulation, whereas a green line indicates normal or controlled glucose levels and lower AGE accumulation.

“The clinical data indicated that the fluorescence ratio could provide better discrimination between individuals with and without diabetes than fluorescence intensity,” Dr Koyluoglu concluded. “Noninvasive measurements of lens autofluorescence may have clinical utility for general health beyond diabetes and its complication[s].”

—Christina Vogt

Reference:

Koyluoglu N. The fluorescence ratıo, as a new parameter for long-term metabolıc control. What & when would you know? Paper presented at: 15th International Congress on Vision Science and Ophthalmology/Eye; August 10-11, 2017. London, UK. http://visionscience.conferenceseries.com/abstract/2017/what-when-would-you-know.